李利在天津调研支持医药产业研发创新工作

Core Viewpoint - The National Medical Products Administration (NMPA) is focusing on enhancing the regulatory framework for pharmaceuticals and medical devices to promote innovation and streamline the approval process for new products [1] Group 1: Regulatory Reforms - The NMPA is implementing a strategy of "early intervention, tailored approaches for each company, comprehensive guidance, and collaborative review" to improve communication and service throughout the product development process [1] - There is an emphasis on replicating and promoting pilot experiences to shorten the review and approval timelines for innovative drugs and medical devices [1] Group 2: Encouragement of Clinical Trials - The NMPA is encouraging the conduct of international multi-center clinical trials to facilitate the simultaneous development, application, review, and market launch of global innovative drugs and medical devices in China [1]